Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα.
about
Cancer immunotherapy: the beginning of the end of cancer?To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic VirusesTissue Specific Promoters in Colorectal CancerEmerging role of Natural killer cells in oncolytic virotherapyPrime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapyA novel cancer vaccine strategy with combined IL-18 and HSV-TK gene therapy driven by the hTERT promoter in a murine colorectal cancer model.T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity.Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.Immune recognition of gene transfer vectors: focus on adenovirus as a paradigm.Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers.Evolution of oncolytic viruses: novel strategies for cancer treatment.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Role of NK cells in immunotherapy and virotherapy of solid tumors.Targeting Melanoma with Cancer-Killing Viruses.Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12.Oncolytic virotherapy for urological cancers.Oncolytic Immunotherapy for Treatment of Cancer.Oncolytic viruses-immunotherapeutics on the rise.Local sustained delivery of oncolytic adenovirus with injectable alginate gel for cancer virotherapy.Immune System, Friend or Foe of Oncolytic Virotherapy?Inflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor DevelopmentOncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.Prospects for combined use of oncolytic viruses and CAR T-cells.Designing and building oncolytic viruses.New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.Advances in the mechanisms of action of cancer-targeting oncolytic viruses.From Benchtop to Bedside: A Review of Oncolytic Virotherapy.Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts.Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model.Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.
P2860
Q26752277-37AFA726-E923-4EBF-B55D-A8A10198DD28Q26767212-E7AA9179-DF19-4923-896E-5A91C5675764Q26773374-6241817E-C884-4330-A4AB-A7CCCAA65859Q27025330-5C3AE59D-C564-415C-8B2F-961D29D1598DQ33551626-B0BD5664-BED8-40E2-B854-BF1D2CA6E817Q34120400-2478456D-AE2D-4D57-9426-99F228604959Q35594838-CB67B417-EC9F-41B5-B6A2-D6EE4E7922F1Q36503451-F961F8FC-0D74-4074-B16F-A2B37F8ACAF9Q36981396-8A825CE5-8B30-4BFA-AF9D-EA5318F72EF9Q37580862-AE46D698-320D-4174-9F94-941629E7DB51Q37706248-43013DB8-B5A6-4B59-B105-9A4E2C8CE031Q37709052-4A6AE0DE-9F33-4BC0-979F-7723D1992012Q38008337-E2509693-520A-4A8C-A76E-F6E841A83B5DQ38073096-B93ACA08-E7AD-414A-8765-3AA5913A3B7EQ38159802-9F507ABA-F431-4A1A-AE74-13FFFC10853FQ38223419-3894F335-EEF4-4A21-9042-030F02601531Q38575116-F1B5FE4E-A590-49DA-A30A-FDBD57167591Q38676416-16D14DE7-08F8-457E-B5F9-B4C1779D8351Q38703318-AB8EB44C-6E20-49A4-A264-05673D6C5244Q38842126-B48BA9BF-6BFC-4143-9884-67073317E6CEQ38848223-EAFD81B3-F447-45E1-93A0-29DB49115A3FQ38919107-8B99A9D0-C692-4110-AA96-9D69804C17C7Q39178068-B9228B33-D773-4D23-96B4-0B9F7224D0C1Q39355854-C5CE5921-F634-42B8-A323-43AA47AB0557Q41684112-28CE6EFF-7F3A-41AC-BD57-79B2C5E8C801Q45324119-D374B7A8-AE79-4564-A289-872EB9805472Q47103891-2DF7AF1C-4755-410B-B321-815FAA0C6EA2Q47547386-21A634A3-662E-4EBC-9F61-1C994BA5E21CQ50056861-1B3E1AF7-7D32-4189-9081-16858BABBE11Q52655195-F9B1D791-A82C-4952-B798-F4ED1525FE4EQ53272922-F1E65C70-86BC-46E0-B375-F36700673C4AQ53883435-46C653DD-F552-4EAC-ADD3-C4CBB1FF4CFAQ55097633-D06EC196-58D2-480C-BC4F-DA5865D699A8Q55509278-4E5A8A65-F330-4A4D-AADD-3CC036A3E79A
P2860
Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Oncolytic adenovirus co-expres ...... xpressing IL-12Rβ2 or IL-18Rα.
@ast
Oncolytic adenovirus co-expres ...... xpressing IL-12Rβ2 or IL-18Rα.
@en
type
label
Oncolytic adenovirus co-expres ...... xpressing IL-12Rβ2 or IL-18Rα.
@ast
Oncolytic adenovirus co-expres ...... xpressing IL-12Rβ2 or IL-18Rα.
@en
prefLabel
Oncolytic adenovirus co-expres ...... xpressing IL-12Rβ2 or IL-18Rα.
@ast
Oncolytic adenovirus co-expres ...... xpressing IL-12Rβ2 or IL-18Rα.
@en
P2093
P2860
P356
P1433
P1476
Oncolytic adenovirus co-expres ...... expressing IL-12Rβ2 or IL-18Rα
@en
P2093
P2860
P2888
P304
P356
10.1038/GT.2011.37
P50
P577
2011-03-31T00:00:00Z